Instil Bio, Inc. (TIL)
NASDAQ: TIL · IEX Real-Time Price · USD
0.405
-0.007 (-1.79%)
Sep 28, 2023, 9:30 AM EDT - Market open
Company Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.
The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Instil Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 192 |
| CEO | Bronson Crouch |
Contact Details
Address: 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 United States | |
| Phone | (972) 499-3350 |
| Website | instilbio.com |
Stock Details
| Ticker Symbol | TIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001789769 |
| CUSIP Number | 45783C101 |
| ISIN Number | US45783C1018 |
| Employer ID | 83-2072195 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bronson Crouch | Chairman and Chief Executive Officer |
| Dr. Sandeep Laumas M.D. | Chief Financial Officer and Chief Business Officer |
| Timothy L. Moore | Chief Operating Officer |
| Dr. Mark E. Dudley Ph.D. | Chief Scientific Officer |
| Sumita Ray J.D. | Chief Legal, Compliance, and Administrative Officer |
| Dr. Robert Hawkins MBBS, Ph.D. | Head of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2023 | 10-Q | Quarterly Report |
| Aug 14, 2023 | 8-K | Current Report |
| Jun 26, 2023 | 8-K | Current Report |
| Jun 14, 2023 | 8-K | Current Report |
| May 11, 2023 | 10-Q | Quarterly Report |
| May 11, 2023 | 8-K | Current Report |
| Apr 28, 2023 | DEFR14A | Filing |
| Apr 24, 2023 | ARS | Filing |
| Apr 24, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2023 | DEF 14A | Other definitive proxy statements |